Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates
Jeffrey Y. W. Mak, Kai‐Chen Wu, Praveer Gupta, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 4, pp. 2186-2204
Closed Access | Times Cited: 19

Showing 19 citing articles:

Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang Tao, Fengli Wang, Reham M. Elhassan, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 6, pp. 2425-2463
Open Access | Times Cited: 86
Medicinal chemistry updates of novel HDACs inhibitors (2020 to present)
Xingrui He, Zi Hui, Li Xu, et al.
European Journal of Medicinal Chemistry (2021) Vol. 227, pp. 113946-113946
Closed Access | Times Cited: 58
Histone deacetylase 7: a signalling hub controlling development, inflammation, metabolism and disease
Yizhuo Wang, Rishika Abrol, Jeffrey Y. W. Mak, et al.
FEBS Journal (2022) Vol. 290, Iss. 11, pp. 2805-2832
Open Access | Times Cited: 37
Large-scale multiplexed mosaic CRISPR perturbation in the whole organism
Bo Liu, Zhengyu Jing, Xiaoming Zhang, et al.
Cell (2022) Vol. 185, Iss. 16, pp. 3008-3024.e16
Open Access | Times Cited: 29
Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects
Jinxiao Ru, Yuxi Wang, Zijia Li, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115800-115800
Closed Access | Times Cited: 10
HDAC7: a promising target in cancer
Cui Liu, Dan Zheng, Xuan Pu, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
N-(2-Aminophenyl)-benzamide Inhibitors of Class I HDAC Enzymes with Antiproliferative and Antifibrotic Activity
Dimitrios Triantafyllos Gerokonstantis, Christiana Mantzourani, Dimitrios Gkikas, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 20, pp. 14357-14376
Closed Access | Times Cited: 8
Sulfur(VI) Fluoride Exchange Chemistry in Solid-Phase Synthesis of Compound Arrays: Discovery of Histone Deacetylase Inhibitors
Tobias Hansen, Daniela Danková, Michael Bæk, et al.
JACS Au (2024) Vol. 4, Iss. 5, pp. 1854-1862
Open Access | Times Cited: 2
The histone deacetylase Hdac7 supports LPS-inducible glycolysis and Il-1β production in murine macrophages via distinct mechanisms
Divya Ramnath, Kaustav Das Gupta, Yizhuo Wang, et al.
Journal of Leukocyte Biology (2021) Vol. 111, Iss. 2, pp. 327-336
Closed Access | Times Cited: 15
Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer
Bidyadhar Sethy, Richa Upadhyay, Iin Narwanti, et al.
APOPTOSIS (2024) Vol. 29, Iss. 11-12, pp. 2047-2073
Open Access | Times Cited: 1
Synthesis of benzoxazole-based vorinostat analogs and their antiproliferative activity
Christiana Mantzourani, Dimitrios Gkikas, Alexandros C. Kokotos, et al.
Bioorganic Chemistry (2021) Vol. 114, pp. 105132-105132
Closed Access | Times Cited: 10
In Silico Identification of Promising New Pyrazole Derivative-Based Small Molecules for Modulating CRMP2, C-RAF, CYP17, VEGFR, C-KIT, and HDAC—Application towards Cancer Therapeutics
Fatima Ezzahra Bennani, Khalid Karrouchi, Latifa Doudach, et al.
Current Issues in Molecular Biology (2022) Vol. 44, Iss. 11, pp. 5312-5351
Open Access | Times Cited: 7
A novel inhibitor of class IIa histone deacetylases attenuates collagen‐induced arthritis
Eunice K. Y. Poon, Ligong Liu, Kai‐Chen Wu, et al.
British Journal of Pharmacology (2024)
Open Access | Times Cited: 1
Tubulin/HDAC dual-target inhibitors: Insights from design strategies, SARs, and therapeutic potential
Zhen Zhang, Rui Su, Juan Liu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 281, pp. 117022-117022
Closed Access | Times Cited: 1
Determination of Sample Concentrations by PULCON NMR Spectroscopy
Jeffrey Y. W. Mak
Australian Journal of Chemistry (2021) Vol. 75, Iss. 2, pp. 160-164
Open Access | Times Cited: 9
Photochemical synthesis of an epigenetic focused tetrahydroquinoline library
Adam I. Green, George M. Burslem
RSC Medicinal Chemistry (2021) Vol. 12, Iss. 10, pp. 1780-1786
Open Access | Times Cited: 6
Synthesis and biological evaluation of ortho -phenyl phenylhydroxamic acids containing phenothiazine with improved selectivity for class IIa histone deacetylases
Kai‐Cheng Hsu, Yunyi Huang, Jung-Chun Chu, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2024) Vol. 39, Iss. 1
Open Access
HDAC7 promotes ovarian cancer malignancy via AKT/mTOR signalling pathway
Qi Feng, Hao Sheng, Xiongxiu Liu, et al.
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 20
Open Access
Dona Flor and her two husbands: Discovery of novel HDAC6/AKT2 inhibitors for myeloid cancer treatment
Karoline B. Waitman, Holli‐Joi Martin, Jorge Antonio Elias Godoy Carlos, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Page 1

Scroll to top